Business Wire

Children and young people encounter multiple forms of gender-based violence – an online course produced by an international project coordinated by Tampere University helps to identify and prevent it

24.1.2022 13:05:00 EET | Business Wire | Press release

Share

Children and young people are exposed to a wide range of gendered violence. However, the phenomenon is poorly understood, which makes helping the victims difficult. The international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project, coordinated by Tampere University, produced an online course to help identify, prevent and address gender-based violence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005334/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University. (Photo: Business Wire)

How do you approach young people who experience discrimination based on their gender expression? How do you deal with offensive images of your student, for example, on social media? And how do you address sexual violence faced by children or young people? Violence against children and youths is often referred to as bullying, even when it is considered assault by the Criminal Code.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University.

Husso leads the international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project coordinated by Tampere University, which has just published a free online course on encountering gender-based violence at schools in English, Finnish and Swedish. The training is also produced in Croatian, Spanish and Catalan.

It is a research-based e-learning package that develops new skills for those working in education, social work and health services. The training is aimed specifically at professionals working with 13–19-year-old teenagers but is also suitable for use with younger and older students. The training looks at the phenomenon from the perspectives of the person experiencing violence, the perpetrator, bystanders, and professionals and experts.

Schools play a pivotal role

Schools play a key role in identifying and addressing violence. The social environment of schools provides an opportunity to learn interaction skills and offers a unique opportunity to influence the perceptions and behaviour of children and young people. At the same time, it enables awareness-raising and change towards more equal relationships and more ethical practices.

“Addressing violence is a prerequisite for promoting equality and sustainable development. This new online training provides tools for preventing, identifying, and addressing violence. It provides information on such issues as digital violence, the impact of violence, good practices and legislation on the subject," says Husso.

“Getting help for problems of violence depends on the problem first being identified and addressed,” she emphasises.

The EraseGBV project has researched gender-based violence and ethical agency in schools and education in Finland, Croatia and Spain. The research partners comprise Tampere University; the University of Zagreb; Blanquerna Ramón Llull University; the Centre for Education, Counselling and Research (CESI); and Conexus.

For more information and instructions on how to register, please see the link to further information and the online course: https://projects.tuni.fi/erasegbv/training-programme/

Photo: In her future projects, Associate Professor Marita Husso will focus on promoting nonviolence and sustainable wellbeing and exploring harmful ideological, institutional and affective practices related to violence. Photo by Hanna-Kaisa Hämäläinen

Tampere University

The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health, and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together, Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enquiries:
Associate Professor Marita Husso
Faculty of Social Sciences, Tampere University
marita.husso@tuni.fi, tel. +358503182510

University Researcher Satu Lidman
Faculty of Social Sciences, Tampere University
satu.lidman@tuni.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye